Rewrite with full clinical detail. Use proper medical terminology. Include dosages, regimen names, biomarker...

Standard Treatment Options

Preferred: Platinum-etoposide chemotherapy with immune checkpoint inhibitor consolidation

For extensive-stage small cell lung cancer (ES-SCLC), the NCCN Guidelines Version 2.2026 recommend platinum-based chemotherapy combined with etoposide as foundational induction therapy, with consideration for immune checkpoint inhibitor (ICI) addition based on recent phase 3 evidence.

• Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1-3, every 21 days × 4 cycles followed by maintenance atezolizumab 1200 mg IV Day 1 every 21 days (Category 2A). This regimen is supported by the CASPIAN trial (durvalumab-based) and represents the preferred approach for patients with ECOG performance status 0-2 without contraindications to immunotherapy.

• Cisplatin AUC 5-6 Day 1 + Etoposide 100 mg/m² Days 1-3, every 21 days × 4 cycles with consideration for concurrent or sequential ICI consolidation. Cisplatin-based regimens may offer superior efficacy in selected patients with adequate renal function (creatinine clearance ≥60 mL/min) and performance status 0-1, though carboplatin is preferred in elderly patients or those with renal compromise.

• Carboplatin AUC 5 Day 1 + Etoposide 100 mg/m² Days 1-3 + Atezolizumab 1200 mg IV Day 1, every 21 days × 4 cycles, followed by maintenance lurbinectedin 3.2 mg/m² + atezolizumab 1200 mg Day 1 every 21 days (Category 2A, per IMforte trial). This approach is recommended for patients achieving at least stable disease after induction chemoimmunotherapy with ECOG PS 0-1 and no history of brain metastases.

• Whole brain radiation therapy (WBRT) for asymptomatic brain metastases: Administer systemic therapy before initiating WBRT per NCCN Guidelines. For symptomatic brain metastases, initiate dexamethasone (10 mg loading dose followed by 4-6 mg maintenance IV/PO every 4-6 hours) and consider WBRT before systemic therapy initiation unless immediate systemic therapy is clinically indicated.

---

Additional Options to Discuss

Immune Checkpoint Inhibitor Consolidation

• Durvalumab 10 mg/kg IV every 2 weeks or Atezolizumab 1200 mg IV every 3 weeks as maintenance therapy following platinum-etoposide induction. The CASPIAN trial (Goldman et al., Lancet Oncol 2021) demonstrated improved overall survival with durvalumab ± tremelimumab consolidation. Current NCCN Guidelines recommend ICI consolidation as standard of care for ES-SCLC patients with adequate performance status and no contraindications.

• Tremelimumab 75 mg IV in combination with durvalumab for selected patients, though monotherapy with single-agent ICI is preferred due to toxicity considerations.

Prophylactic Cranial Irradiation (PCI)

• PCI at 25 Gy in 10 fractions (2.5 Gy/fraction) or 30 Gy in 12 fractions (2.5 Gy/fraction) for patients achieving complete or near-complete response to initial therapy. PCI reduces symptomatic brain relapse incidence from approximately 40-50% to 15-20% in responders. Recommend brain MRI (preferred over CT for sensitivity in detecting micrometastases) prior to PCI initiation to exclude progressive brain disease.

Stereotactic Radiosurgery (SRS) for Oligometastatic Brain Disease

• SRS to dominant lesions (typically ≤3-4 lesions, each ≤3-4 cm) as alternative to WBRT for selected patients with limited intracranial disease burden. Doses typically range from 15-24 Gy in single fraction depending on lesion size and proximity to critical structures. Consider SRS followed by delayed WBRT versus SRS alone based on intracranial disease burden and systemic disease control.

Second-Line Systemic Therapy

• Lurbinectedin 3.2 mg/m² IV over 60 minutes every 21 days for platinum-sensitive relapsed SCLC (chemotherapy-free interval ≥3 months). FDA-approved based on phase 2 basket trial data (Trigo et al., Lancet Oncol 2020) demonstrating objective response rate of 35% in second-line setting.

• Topotecan 1.5 mg/m²/day IV Days 1-5 every 21 days (intravenous formulation) or 2.3 mg/m²/day orally Days 1-5 every 21 days for platinum-sensitive disease. Established second-line option with response rates of 24-25% in phase 3 trials.

• Platinum-etoposide rechallenge (carboplatin AUC 5 + etoposide 100 mg/m² Days 1-3 every 21 days) for platinum-sensitive relapse (chemotherapy-free interval ≥6 months). Response rates of 40-50% support rechallenge in appropriately selected patients.

• Irinotecan 50 mg/m² IV weekly × 4 weeks every 6 weeks as alternative second-line option, particularly for patients with platinum-sensitive disease and adequate performance status.

---

Clinical Trial Opportunities

DLL3-Targeted Immunotherapy

• Tarlatamab-dlle (Ionis/Genentech) — Anti-DLL3 bispecific antibody. Tarlatamab demonstrated clinical activity in relapsed/refractory SCLC with objective response rates of 42-44% in phase 2 studies. DLL3 is expressed on >95% of SCLC tumors, making this a rational therapeutic target. Recommended dose: 10 mg IV weekly after 5 mg loading dose.

Combination Immunotherapy Approaches

• Nivolumab + Ipilimumab ± chemotherapy trials for ES-SCLC. Dual checkpoint inhibition targeting PD-1 and CTLA-4 may enhance anti-tumor immunity, though toxicity profile requires careful patient selection and monitoring.

• PD-L1 expression-stratified trials — Patients with PD-L1 ≥50% expression may derive greater benefit from ICI monotherapy or combination approaches. Consider PD-L1 immunohistochemistry (IHC) testing if not previously performed.

PARP Inhibitor Studies

• Olaparib, rucaparib, or talazoparib in SCLC with documented homologous recombination deficiency (HRD) or BRCA1/2 mutations. Approximately 5-10% of SCLC tumors harbor BRCA mutations or demonstrate HRD phenotype. Comprehensive genomic profiling (CGP) via tissue or circulating tumor DNA (ctDNA) is recommended for rare cases of non-smoking or lightly smoking patients with ES-SCLC.

CAR-T Cell Therapy Trials

• CD56-targeted CAR-T approaches — CD56 (NCAM) is expressed on SCLC cells. CD56-negative tumors may represent distinct biology warranting alternative immunotherapeutic strategies. Enrollment in CAR-T trials should be considered in consultation with centers with expertise in transformed SCLC or rare SCLC phenotypes.

Novel Chemotherapy Agents

• Lurbinectedin-based combinations — Ongoing trials evaluating lurbinectedin + atezolizumab maintenance (IMforte trial, Paz-Ares et al., Lancet 2025) demonstrate improved progression-free survival and overall survival compared to atezolizumab monotherapy.

---

Supportive Care and Navigation Resources